financetom
Business
financetom
/
Business
/
Market Chatter: Paramount Global Sale Hinges on FCC Approval
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Market Chatter: Paramount Global Sale Hinges on FCC Approval
May 7, 2024 1:22 PM

04:05 PM EDT, 05/07/2024 (MT Newswires) -- Paramount Global's ( PARAA ) sale will depend on getting regulatory clearance from the US Federal Communications Commission, Bloomberg reported Tuesday, citing Byron Allen, who is pursuing a transaction to acquire the film and television company.

"My advice would be to walk into the FCC with someone who is FCC approved," Allen reportedly said. "We are broadcasters first, and we are FCC approved. That is the key."

Allen reportedly bid $28.58 and $21.53 per voting and non-voting share of Paramount, respectively. Including existing debt, the total value of the deal is said to be around $30 billion.

Apollo Global (APO) and Sony Group's jointly owned company Skydance Media also offered to acquire Paramount for $26 billion, according to the report.

Paramount, Apollo, Sony, and Skydance did not immediately respond to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
AbbVie Closes Bretisilocin Acquisition
AbbVie Closes Bretisilocin Acquisition
Oct 17, 2025
09:28 AM EDT, 10/17/2025 (MT Newswires) -- AbbVie ( ABBV ) said Friday it has closed the acquisition of Gilgamesh Pharmaceuticals' lead investigational candidate bretisilocin. Bretisilocin is a psychedelic compound in phase 2 clinical development for the treatment of patients with moderate to severe major depressive disorder, AbbVie ( ABBV ) said. ...
Neurocrine Biosciences Says Late-Stage Movement Disorder Study Shows Ingrezza's Therapeutic Efficacy at Lowest Available Dose
Neurocrine Biosciences Says Late-Stage Movement Disorder Study Shows Ingrezza's Therapeutic Efficacy at Lowest Available Dose
Oct 17, 2025
09:29 AM EDT, 10/17/2025 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) said Friday that a new post-hoc analysis of a late-stage study showed clinically meaningful improvements in tardive dyskinesia symptoms in patients treated with Ingrezza at the lowest available dose of 40 mg. The company said 90% of participants who received continuous treatment for 48 weeks improved by at...
Visionary Completes Controlling Stake in Sikang Health Industry Joint Venture Platform, Deepening Global Layout of TCM Health Preservation
Visionary Completes Controlling Stake in Sikang Health Industry Joint Venture Platform, Deepening Global Layout of TCM Health Preservation
Oct 17, 2025
TORONTO, Oct. 17, 2025 /PRNewswire/ -- Visionary Holdings Inc. ( GV ) , a Nasdaq-listed enterprise, announced today that it has completed the equity adjustment of Sikang (Guangzhou) Health Industry Investment Co., Ltd. (hereinafter referred to as the Joint Venture Company), a joint venture established with Guangzhou Sikang Investment Holding Co., Ltd. (hereinafter referred to as Guangzhou Sikang), and officially...
Form 8.3 - Spectris plc
Form 8.3 - Spectris plc
Oct 17, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Balyasny Asset Management LP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...
Copyright 2023-2026 - www.financetom.com All Rights Reserved